Inverness Medical Innovations Announces Fourth Quarter 20...(p expense (ii) non-recurring cha...)

expense, (ii) non-recurring charges and income, and (iii) certain

other charges and income that have a significant positive or

negative impact on results yet do not occur on a consistent or

regular basis in its business. In determining whether a particular

item meets one of these criteria, management considers facts and

circumstances that it believes are relevant. Management believes

that excluding such charges and income from income or loss allows

investors and management to evaluate and compare the Company's

operating results from continuing operations from period to period

in a meaningful and consistent manner. Due to the frequency of

their occurrence in its business, the Company does not adjust net

income or loss for the costs associated with litigation, including

payments made or received through settlements. It should be noted

that "net income or loss on an adjusted cash basis" is not a

standard financial measurement under accounting principles generally

accepted in the United States of America ("GAAP") and should not be

considered as an alternative to net income or loss or cash flow from

operating activities, as a measure of liquidity or as an indicator

of operating performance or any measure of performance derived in

accordance with GAAP.

(b) Restructuring charge associated with the decision to close

facilities of $6.7 million and $8.9 million for the year ended

December 31, 2007 and 2006, respectively. The $6.7 million charge

for the year ended December 31, 2007 includes: $2.0 million charged

to cost of sales, $2.5 million charged to research and development,

and $2.2 million charged to selling, general and administrative

expense. The $
'/>"/>